GlycoDesign ends Phase II GD0039 enrollment

GlycoDesign (TSE:GD) discontinued enrollment in North American and French Phase II studies of its GD0039 carbohydrate processing enzyme inhibitor to treat metastatic renal cell carcinoma following tum...